PROCUREMENT OF TISSUE FOR AUTOLOGOUS TUMOR VACCINE PREPARATION

采购用于自体肿瘤疫苗制备的组织

• 批准号: 7950662
• 负责人: MALCOLM K. BRENNER
• 金额: $ 0.03万
• 依托单位: BAYLOR COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-12-01 至 2009-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7950662
• 关键词: Adenovirus Vector; Animals; Autologous; Blood; Bone Marrow Neoplasms; Cancer Vaccines; Cells; Clinical Research; Companions; Computer Retrieval of Information on Scientific Projects Database; Funding; Genes; Grant; Human; Immune response; Immunity; Individual; Institution; Malignant Neoplasms; Neural Crest Cell; Neuroblastoma; Patients; Preparation; Production; Protocols documentation; Research; Research Personnel; Resources; Skin; Source; System; Tissue Procurements; Tissues; Tumor Tissue; United States National Institutes of Health; Vaccines; cytokine; genetically modified cells; neoplastic cell; research study; response; tumor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a procurement only protocol This is a companion protocol to the following GCRC supported research studies: H-11541, 11967, 6408, 6442, 8354 HYPOTHESIS Using adenoviral vectors to genetically modify cells obtained from patient tissue to produce cytokines, will enable production of autologous vaccines to induce anti-tumor response. SPECIFIC AIMS The purpose of this study is to obtain tissue (tumor, bone marrow, blood or skin) from patients, from which to determine our ability to create cells that have been genetically modified by adenoviral vectors to produce cytokines. If this is successful, patients may be offered treatment on an autologous vaccine study. BACKGROUND AND SIGNIFICANCE Studies in animals and in humans have shown that tumor cells genetically modified to express immunomodulatory genes can induce a potent anti-tumor immune response. Importantly, this immunity can be directed not just against the genetically modified cells, but also against tumor cells elsewhere in the body. We are using this approach to treat individuals with advanced malignancies, of both the hemopoeitic system and neural crest cells(neuroblastoma). Since human tumors are antigenically disparate, each tumor "vaccine" comes from the patient's own tumor. The purpose of this protocol is to allow us to collect adequate amounts of tumor-bearing tissue.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 这是一个采购专用协议 这是以下GCRC支持的研究的配套方案： H-11541、11967、6408、6442、8354 假设 使用腺病毒载体对从患者组织获得的细胞进行遗传修饰以产生细胞因子，将使得能够产生自体疫苗以诱导抗肿瘤应答。 具体目标 本研究的目的是从患者中获得组织（肿瘤，骨髓，血液或皮肤），从中确定我们创建经腺病毒载体遗传修饰的细胞以产生细胞因子的能力。如果这是成功的，患者可能会提供治疗的自体疫苗研究。 背景和意义 在动物和人类中的研究已经表明，经遗传修饰以表达免疫调节基因的肿瘤细胞可以诱导有效的抗肿瘤免疫应答。重要的是，这种免疫力不仅可以针对转基因细胞，还可以针对身体其他部位的肿瘤细胞。我们正在使用这种方法来治疗晚期恶性肿瘤，造血系统和神经嵴细胞（神经母细胞瘤）。由于人类肿瘤的抗原性不同，每种肿瘤“疫苗”都来自患者自己的肿瘤。本方案的目的是使我们能够收集足够量的肿瘤组织。